RVXCF News Alert Resverlogix Corp (RVXCF) 0.6050 02/15/2015
Post# of 64074
Posted On: 02/15/2015 12:23:47 PM
Resverlogix Corp (RVXCF) 0.6050 $RVXCF
Resverlogix Presents at Biotech Showcase During JP Morgan Week
PR Newswire - Wed Jan 14, 7:00PM CST
Resverlogix Corp. (TSX:RVX) (the "Company"
today announced that Donald McCaffrey, president and chief executive officer presented at the 7th Annual Biotech Showcase Conference 2015 during JP Morgan week. The presentation can be accessed via the following link: http://edge.media-server.com/m/p/5wz2z9gn
RVX.TO: 0.82 (+0.02)
Resverlogix Names Michael Sweeney, M.D., as Senior Vice President of Clinical Development
PR Newswire - Mon Nov 03, 4:05PM CST
Resverlogix Corp. (TSX:RVX) today announced the appointment of Michael T. Sweeney, M.D., as senior vice president of clinical development.
RVX.TO: 0.82 (+0.02)
Resverlogix Corporate Update Conference Call & Webcast Announcement
PR Newswire - Wed Oct 01, 1:00PM CDT
TSX Exchange Symbol: RVX
RVX.TO: 0.82 (+0.02)
Resverlogix Corp. Closes Additional $30 million from Citibank Loan
PR Newswire - Fri Aug 15, 4:00PM CDT
TSX Exchange Symbol: RVX
RVX.TO: 0.82 (+0.02)
Resverlogix Corp. Shareholders Approve Additional $30 million from Citibank Loan
PR Newswire - Wed Aug 13, 4:01PM CDT
TSX Exchange Symbol: RVX
RVX.TO: 0.82 (+0.02)
Restenosis - Pipeline Review, H1 2014
M2 - Fri Jun 27, 5:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fzlqdr/restenosis) has announced the addition of the "Restenosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Restenosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Restenosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Restenosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Restenosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Shire Plc - Resverlogix Corp. - CytoTools AG - Angelini Group - Viron Therapeutics, Inc. - AIM Therapeutics Inc. - CSPC NBP Pharmaceutical Co.,ltd - XBiotech USA, Inc. For more information visit http://www.researchandmarkets.com/research/fzlqdr/restenosis
SHPG: 239.82 (+6.11)
Resverlogix Presents at Biotech Showcase During JP Morgan Week
PR Newswire - Wed Jan 14, 7:00PM CST
Resverlogix Corp. (TSX:RVX) (the "Company"
today announced that Donald McCaffrey, president and chief executive officer presented at the 7th Annual Biotech Showcase Conference 2015 during JP Morgan week. The presentation can be accessed via the following link: http://edge.media-server.com/m/p/5wz2z9gn RVX.TO: 0.82 (+0.02)
Resverlogix Names Michael Sweeney, M.D., as Senior Vice President of Clinical Development
PR Newswire - Mon Nov 03, 4:05PM CST
Resverlogix Corp. (TSX:RVX) today announced the appointment of Michael T. Sweeney, M.D., as senior vice president of clinical development.
RVX.TO: 0.82 (+0.02)
Resverlogix Corporate Update Conference Call & Webcast Announcement
PR Newswire - Wed Oct 01, 1:00PM CDT
TSX Exchange Symbol: RVX
RVX.TO: 0.82 (+0.02)
Resverlogix Corp. Closes Additional $30 million from Citibank Loan
PR Newswire - Fri Aug 15, 4:00PM CDT
TSX Exchange Symbol: RVX
RVX.TO: 0.82 (+0.02)
Resverlogix Corp. Shareholders Approve Additional $30 million from Citibank Loan
PR Newswire - Wed Aug 13, 4:01PM CDT
TSX Exchange Symbol: RVX
RVX.TO: 0.82 (+0.02)
Restenosis - Pipeline Review, H1 2014
M2 - Fri Jun 27, 5:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fzlqdr/restenosis) has announced the addition of the "Restenosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Restenosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Restenosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Restenosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Restenosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Shire Plc - Resverlogix Corp. - CytoTools AG - Angelini Group - Viron Therapeutics, Inc. - AIM Therapeutics Inc. - CSPC NBP Pharmaceutical Co.,ltd - XBiotech USA, Inc. For more information visit http://www.researchandmarkets.com/research/fzlqdr/restenosis
SHPG: 239.82 (+6.11)
(0)
(0)Scroll down for more posts ▼